Florian Fitzal

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

Michael Gnant, Brigitte Mlineritsch, Walter Schippinger et al. · New England Journal of Medicine · 2009 · 1K citations · Full text

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Martin Filipits, Margaretha Rudas, R. Jakesz et al. · Clinical Cancer Research · 2011 · 703 citations · Full text

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

Michael Gnant, Georg Pfeiler, Peter Dubsky et al. · The Lancet · 2015 · 543 citations

Breast Oncology, Oncology, Clinical Trials +7

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

Michael Gnant, Brigitte Mlineritsch, G. Luschin-Ebengreuth et al. · The Lancet Oncology · 2008 · 393 citations

Zoledronic Acid, Breast Oncology, Bone Health +9

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Michael Gnant, Martin Filipits, Richard Greil et al. · Annals of Oncology · 2013 · 392 citations · Full text

Surgical Oncology, Breast Oncology, Recurrence Score +10